[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.205.176.107. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Article
March 1980

Phenothiazine Levels in Plasma and Red Blood CellsTheir Relationship to Clinical Improvement in Schizophrenia

Author Affiliations

From the Illinois State Psychiatric Institute, Chicago (Drs Casper, Chang, and Davis); the Department of Psychiatry, Abraham Lincoln School of Medicine, Chicago (Dr Casper); the Department of Psychiatry, University of Cincinnati Medical Center (Dr Garver); the National Psychopharmacology Laboratory, Knoxville, Tenn (Dr Dekirmenjian); and the Pritzker School of Medicine, Chicago (Dr Davis).

Arch Gen Psychiatry. 1980;37(3):301-305. doi:10.1001/archpsyc.1980.01780160071008
Abstract

• A controlled study investigated the relationship between steady-state plasma and RBC concentrations of the phenothiazine derivative butaperazine maleate and the therapeutic response in 24 hospitalized schizophrenic patients who received constant maintenance doses of butaperazine during the first two weeks of treatment. Butaperazine concentrations in RBCs correlated significantly with clinical improvement in an inverted U-shaped pattern, whereas plasma levels of butaperazine were not significantly related to clinical response. Both plasma and RBC levels of butaperazine showed large interpatient variations. The level of RBC-bound drug might be a better peripheral correlate of drug levels in the brain than are drug levels in plasma. Thus, monitoring drug levels in RBCs might have an advantage over measuring drug levels in plasma. These findings might not allow generalization to other antipsychotic agents.

×